Ambitions Enterprise Management (AHMA) : 6-week performance

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. 

• Sector: Consumer Cyclical
• Industry: Travel Services
• Full Time Employees: 43
• Founded  in 2023 
• HQ in Dubai, the United Arab Emirates

The stock experienced a significant decline during regular trading hours on December 5, 2025, amid heightened volatility typical for a recent IPO. Trading was halted briefly around 9:55 AM ET due to rapid price swings, resuming shortly after, which exacerbated the downward move. This follows a pattern of sharp fluctuations, including a 12.23% drop on December 4 and prior surges tied to subsidiary appointments for global events announced late last week. No new announcements or external events appear to have triggered the move, pointing to profit-taking and thin liquidity in this UAE-based MICE firm's shares. Volume spiked to over 1 million shares, amplifying the intraday plunge based on available reports.

=========

As a UAE-based MICE (meetings, incentives, conferences, and exhibitions) and tourism services provider, the Company serves a global client base by delivering expert event management and seamless, one-stop travel solutions. Guided by an experienced management team and supported by partnerships across the tourism and hospitality industries in the Middle East, Europe, Africa, and the Americas, the Company executes large-scale events for clients from diverse sectors. Additionally, the Company manages bespoke travel experiences, providing a one-stop guided tour service that streamlines travel across the UAE and its neighboring countries, as well as to other global destinations.

For more information, please visit https://ir.ambitions.ae 

American Bitcoin (ABTC) : 3-month performance

American Bitcoin Corp. is a bitcoin accumulation platform company.

September 3, 2025: first day of trading on the Nasdaq, following a merger with Gryphon Digital Mining. The stock experienced significant volatility, opening around $8, surging to a high of $14.52, and ultimately closing at $8.04, up 16.5% for the day. 

• Parent organization: Hut 8 Corp. (NASDAQ:HUT)
• Founders: Eric Trump, Donald Trump Jr.
• Founded: March 2025
• Headquarters: Miami, Florida
• Incorporated: Delaware
• www.americanbtc.com

Bearish Put Activity:

• ABTC Weekly Dec05 1.5 puts are seeing interest with the underlying stock down 38% (volume: 9.0K, open int: 50, implied vol: ~211%, prev day implied vol: 97%). Co is expected to report earnings mid-February.

American Bitcoin Corp (ABTC) shares plunge over 50% Tuesday with multiple trading halts as Eric Trump cites pre-merger private placement share unlock driving heavy volume and steep selloff.

 

 

 

 

 

About American Bitcoin

American Bitcoin is a majority-owned subsidiary of Hut 8 focused exclusively on industrial-scale Bitcoin mining and strategic Bitcoin reserve development. The company combines Hut 8's proven mining operations, cost-efficient infrastructure development capabilities, and disciplined approach to capital allocation with Eric Trump's commercial acumen, capital markets expertise, and commitment to the advancement of decentralized financial systems. For more information, visit www.americanbtc.com.

Ero Copper (ERO) +17%

Ero Copper Corp. engages in the exploration, development, and production of mining projects in Brazil. 

Its flagship asset includes Caraíba operations that comprise the production and sale of copper concentrates located in northeastern Bahia State, Brazil, as well as gold and silver produced and sold as by-products. 

• Sector: Basic Materials
• Industry: Copper
• Full Time Employees: 3,690
• Incorporated in 2016 
• Headquartered in Vancouver, Canada
• https://erocopper.com

Cidara Therapeutics (CDTX) to be acquired by Merck (MRK) for $9.2B or $221.50 per share

Cidara Therapeutics to be acquired by Merck (MRK) for $221.50 per share in cash

• Merck (MRK) agreed to acquire Cidara Therapeutics (CDTX) for $221.50/share in cash, valuing the transaction at ~$9.2B, as part of its strategy to broaden its infectious disease pipeline.
• Deal centers on CD388, a long-acting, strain-agnostic antiviral in Phase 3 (ANCHOR) for preventing influenza in high-risk individuals; the candidate has Breakthrough Therapy and Fast Track designations and showed strong efficacy in the Phase 2b NAVIGATE trial.
• CD388 combines a neuraminidase inhibitor with a proprietary Fc-antibody fragment, aiming to provide a durable prevention option beyond vaccines and traditional antivirals.
  
• Boards of both companies have approved the transaction; closing is expected in Q1 2026, pending a successful tender offer, HSR clearance, and customary conditions.

  

 

The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 38
• Incorporated in 2012 
• Based in San Diego, California
• https://www.cidara.com

Leifras (LFS) began trading on the Nasdaq on Thur 9 Oct 25

Headquartered in Tokyo, Leifras is a sports and social business company dedicated to youth sports and community engagement. 

 

The Company primarily provides services related to the organization and operations of sports schools and sports events for children. As of December 31, 2024, Leifras was recognized as one of Japan's largest operators of children's sports schools in terms of both membership and facilities by Tokyo Shoko Research. 

• Headquarters: Japan
• Founded: August 27, 2001
• https://leifras.co.jp/

Scholar Rock (SRRK) reported Q3 earnings on Fri 14 Nov 25 (b/o)

Scholar Rock Holding Corp. is a biopharmaceutical company.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 128
• Founded by Timothy A. Springer and Leonard I. Zon in  2012
• Headquartered in Cambridge, Massachusetts.
• https://www.scholarrock.com

 

The company announced the results of its earnings performance in the third quarter of the year, where it widened its net loss by 58 percent to $102 million from $64.5 million in the same period last year, pulled down by a 60 percent higher operating loss of $103.5 million versus $64.78 million year-on-year.

Scholar Rock investor sentiment was boosted by the progress of its drug candidate for spinal muscular atrophy (SMA).

In an updated report, Scholar Rock Holding Corp. (NASDAQ:SRRK) said that it completed “constructive and collaborative” in-person meeting with the Food and Drug Administration last Wednesday, November 12, for its biologics license application of apitegromab.

Scholar Rock Holding Corp.  said BLA resubmission and US launch is anticipated by next year.

Additionally, it said that it targets to secure the approval of the European Medicines Agency (EMA) to sell apitegromab to Europe by mid 2026.

Figure Technology Solutions (FIGR) reported Q3 earnings on Thur 13 Nov 25 (a/h)

• Strong Q3 2025 earnings beat, with net income tripling year-over-year, fueled the 21.62% intraday gain

 

Figure Technology Solutions released its Q3 2025 results after market close on November 13, revealing earnings per share of $0.34, surpassing analyst estimates, alongside revenue of $156.37 million driven by robust growth in its tokenized consumer loan marketplace. Net income soared nearly 227% to approximately $90 million, while adjusted EBITDA climbed 75% to $86 million, highlighting the success of its blockchain-based lending platform amid expanding partnerships and marketplace volumes. The earnings call on November 14 at market open amplified positive forward guidance on SMB lending and tokenization initiatives, prompting investor enthusiasm and high trading volume that propelled the sharp price advance during regular hours.

===Novo Nordisk (NVO) launches bidding war with Pfizer (PFE) for US obesity biotech Metsera (MTSR)

Novo Nordisk makes $6.5 billion acquisition offer for Metsera (MTSR), declared superior to Pfizer's prior bid by Metsera's board and potentially triggering a bidding war for the obesity drug developer.

• Pfizer has 4 days to respond to this bid
• Mon 11/3: Pfizer files second lawsuit to block Novo Nordisk's Metsera acquisition with counter bid deadline tomorrow, and is set to report earnings where management will address key strategic questions.

Oct 30, 2025 : Pfizer Addresses Proposal for Metsera

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk. The proposal is illusory and cannot qualify as a superior proposal under Pfizer’s agreement with Metsera, and Pfizer is prepared to pursue all legal avenues to enforce its rights under its agreement.

***

Metsera (MTSR) shares jumped nearly 19% premarket on Thursday after Bloomberg reported that Danish drugmaker Novo Nordisk (NVO) has made a higher offer for the obesity startup, aiming to outmatch Pfizer’s (PFE) previously agreed deal and strengthen its dominance in the fast-growing weight-loss drug market.

Novo, which had made an earlier offer before Metsera’s $4.9 billion agreement with Pfizer, has now returned with an improved proposal in both value and structure, the report said, citing sources. The companies are in advanced discussions, and a potential agreement could be reached as soon as Thursday, though no final decision has been made.

Pfizer’s deal, announced in September, included $47.50 per share upfront and up to $22.50 per share in milestone payments. A Metsera deal would deal a setback to Pfizer (PFE), which is struggling with declining Covid vaccine sales and looming patent expirations after its own obesity pill failed due to safety issues.

Novo Nordisk (NVO), though leading in weight loss, is also under pressure to develop next-generation treatments after its CagriSema drug underperformed, as it seeks to stay ahead of Eli Lilly (LLY).

Metsera’s (MTSR) shares have nearly tripled this year to $52.21, valuing the company at about $5.5 billion. Pfizer (PFE) shares were little changed, while Novo Nordisk (NVO) slipped 1.5% in Copenhagen.

The firm is developing next-generation obesity treatments, including a long-acting amylin analogue that could require less frequent dosing than the market-leading drugs from Novo Nordisk’s (NVO) and Eli Lilly’s (LLY). Amylin-based drugs are seen as a gentler alternative to GLP-1 treatments like Wegovy and Zepbound, which often cause nausea and vomiting.

Grupo Aeroméxico's IPO

Overview of Grupo Aeroméxico's IPO

Grupo Aeroméxico, S.A.B. de C.V., Mexico's flagship airline and the country's only full-service carrier offering long-haul wide-body flights, is preparing for a dual listing on the New York Stock Exchange (NYSE) and the Mexican Stock Exchange (Bolsa Mexicana de Valores, BMV). This marks the airline's return to public markets after delisting in 2022 following its emergence from Chapter 11 bankruptcy protection amid the COVID-19 crisis. The IPO process began with an initial SEC filing in May 2024, followed by a registration statement in September 2025, and terms were unveiled in mid-October 2025.
The offering is backed by major investors, including Apollo Global Management (a key shareholder post-restructuring) and Delta Air Lines (which holds a 20% stake and has agreed to a four-year lockup on its shares). Aeroméxico, founded in 1934 and a co-founder of the SkyTeam alliance, operates flights to every major Mexican city and 52 international destinations across 22 countries, with a focus on high-demand leisure routes like Cancun and Puerto Vallarta.Key IPO Details

Aspect	Details
Ticker Symbol	AERO (NYSE for American Depositary Shares/ADS; BMV for ordinary shares)
Shares Offered	- U.S.: 11.73 million ADS (each representing 10 ordinary shares) - Company: 7.39 million ADS (primary) - Selling shareholders: 4.33 million ADS (secondary) - Mexico: 7 million new shares + 20.46 million from selling shareholders
Price Range	$18–$20 per ADS
Expected Proceeds	- U.S. IPO: $223–$234 million (midpoint: $222.8 million) - Total with private placement: Up to $314 million (includes $25 million from PAR Investment Partners at a 5% discount to IPO price)
Valuation Target	Up to $2.92 billion (fully diluted)
Underwriters	Joint book-runners: Barclays, Morgan Stanley, J.P. Morgan, Evercore ISI Other book-runners: Apollo Global Securities, Citigroup, Deutsche Bank Securities, Goldman Sachs, BNP Paribas, BTG Pactual, Santander
Expected Timeline	- Roadshow: Late October 2025 - Pricing: Potentially week of October 28, 2025 - Trading start: Shortly after pricing (exact date TBD)
Use of Proceeds	Primarily for general corporate purposes, including debt repayment and fleet expansion; secondary shares benefit selling shareholders

Financial Highlights (Trailing 12 Months Ended June 30, 2025)Aeroméxico reported strong post-restructuring performance, driven by robust demand in the Mexico-U.S. transborder market and leisure travel:

• Revenue: $5.42 billion
• Net Income: $360.8 million
• Market Share: 36.3% of total passengers to/from/within Mexico (per Mexico's Federal Aviation Agency)
• Fleet: Operates ~140 aircraft, with plans for growth in wide-body international routes.

Market Context and RisksThis IPO follows LATAM Airlines' $456 million NYSE relisting in July 2024, signaling recovery in Latin American aviation. Mexico's 2.8% GDP growth in 2025 and rising tourism support demand, but investors should note risks like fuel price volatility, geopolitical tensions affecting travel, and currency fluctuations (peso vs. USD). The dual U.S.-Mexico structure aims to attract global capital while relisting locally.

Arcutis Biotherapeutics (ARQT) reported earnings on Tue 28 Oct 25 (b/o)

• Arcutis Biotherapeutics reports Q3 2025 results with $99.2M in ZORYVE sales, $7.4M net income, issues 2026 revenue guidance, and outlines growth strategy at Investor Day presentation.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. 

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 342
• Incorporated in 2016 
• Headquartered in Westlake Village, California.
• https://www.arcutis.com

IPO: Jan 31, 2020

Ticker: ARQT

 

 

 

 

Arcutis Biotherapeutics announces third quarter 2025 results; provides initial 2026 full year net product sales guidance of $455-$470 mln

WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achieve sustainable growth and reported financial results for the quarter ended September 30, 2025.

World's most valuable private companies

1. OpenAI: $500 billion

2. SpaceX: $400 billion

3. ByteDance: $330 billion

 4. Anthropic: $183 billion

 5. xAI: $113 billion

 6. Databricks: $100 billion

 7. Stripe: $92 billion

 8. Revolut: $75 billion

 9. Shein: $66 billion